Regulation of Cutaneous Malignancy by γδ T Cells

By M. Girardi, D. Oppenheim, C. Steele, Julia M. Lewis, E. Glusac, R. Filler, P. Hobby, B. Sutton, R. Tigelaar, A. Hayday. Science, 2001

953 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/8594d18fe4125277f772825c3182cada64972694

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Steinle
2. I. Waldhauer
3. J. Snyder-Cappione
4. Anna C. Belkina
5. S. Gasser
6. W. Deng
7. N. Xiong
8. Heiyoun Jung

In Oncology

1. J. Snyder-Cappione
2. Anna C. Belkina
3. A. Steinle
4. Douglas A. Lauffenburger
5. D. Raulet
6. I. Waldhauer
7. N. Xiong

Citations in the corpus

• Gammadelta T cells for immune therapy of patients with lymphoid malignancies. (2003, methodology): “1 106 4 62 (3-153) 45 (0-122) 0/4 (0) 23 (18-27) 8 ( 38-54) 0/2 (0) 183 (82-426) 322 (0-1253) 3/4 (75) 2 106 3 65 (52-98) 60 (19-121) 2/3 (66) 81 ( 37-103) 93 (79-291) 2/3 (66) 186 (62-230) 124 (122-571) 3/3 (100)”
• Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding (2002, background): “It has been shown that expression of ligands for NKG2D is associated with malignant transformation (15), and MICA expression was described for many epithelial tumors.”